EMA, AMA and African Regulators Unite to Accelerate Ebola Clinical Trials
Decision brief
Answer first · skim in under a minute
EMA's Emergency Task Force is engaging with the African Medicines Agency and its national regulatory authorities to discuss clinical trial designs and medical countermeasures for the ongoing Ebola outbreak caused by the Bundibugyo virus in DRC and Uganda.
EMA's Emergency Task Force is working with the African Medicines Agency and African national regulators to align clinical trial designs for Bundibugyo Ebola countermeasures after WHO declared a May 2026 public health emergency of international concern spanning the Democratic Republic of the Congo and Uganda.
Contents9 sections
Key Takeaways
- EMA describes the collaboration as the first public health emergency in which it works with an operational AMA alongside participating African NRAs.
- WHO declared a Bundibugyo PHEIC on 17 May 2026 after laboratory-confirmed cases in Ituri Province, DRC, and imported cases in Kampala, Uganda.
- WHO notes no licensed vaccine or specific therapeutic exists for Bundibugyo virus disease, unlike Zaire ebolavirus products.
- ETF–AMA discussions cover prophylaxis, post-exposure prophylaxis, and treatment trial designs from early to pivotal studies.
What did EMA announce about African regulatory coordination?
According to the EMA news release, the Emergency Task Force is engaging AMA and its national regulatory authorities, leveraging WHO-AFRO AVAREF expertise, to discuss clinical trial designs and medical countermeasures for the Bundibugyo outbreak.
EMA frames the work as support for efficient, coordinated, and timely regulatory responses, building on prior AVAREF joint-review experience from earlier Ebola outbreaks.
The agency says ETF, AMA, and African NRA experts have already started selected discussions with developers, academia, and funders.
What is the outbreak status that triggered the PHEIC?
On 17 May 2026, WHO determined that Bundibugyo virus disease in DRC and Uganda constitutes a PHEIC under Article 12 of the IHR (2005).
The WHO Director-General determination cited confirmed cases in Ituri Province and two laboratory-confirmed cases in Kampala among travelers from DRC as of mid-May 2026.
A related WHO Disease Outbreak News item recounts INRB confirmation of Bundibugyo in Ituri samples and Uganda's imported-case declaration.
Why does Bundibugyo change the countermeasure playbook?
WHO emphasizes that licensed Zaire-focused vaccines and therapeutics are not established for Bundibugyo, and that diagnostic assays tuned to Zaire may miss Bundibugyo—contributing to delayed detection.
That gap is why EMA–AMA trial-design talks span vaccines, monoclonal antibodies, antivirals, and post-exposure prophylaxis rather than simple label extensions of existing Zaire products.
Developers should expect ICH-aligned evidentiary expectations even under emergency timelines, according to EMA's emphasis on solid scientific evidence for flexible decisions.
What should vaccine and therapeutics BD teams do now?
Engage ETF/AMA early with adaptive protocols covering prophylaxis and treatment across age groups, because design criteria are being set during the emergency.
Align diagnostics strategy with Bundibugyo-capable assays before promising enrollment rates based on Zaire rapid tests.
Coordinate with AVAREF joint-review pathways that African regulators have used in prior filovirus emergencies.
What remains unproven?
Regulatory coordination is not the same as product authorization. No Bundibugyo-specific vaccine or therapeutic approval is established in the EMA or WHO materials cited here.
Candidate shortlists circulating in secondary coverage should be treated as provisional until sponsors publish protocols and regulators confirm selected arms.
Case counts evolve quickly in outbreak settings; use WHO updates rather than static mid-May snapshots for operational planning.
Related NovaPharma coverage
- Ebola disease intelligence hub
- EU clinical trial recruitment template coverage
- Data harmonization in clinical research
Frequently Asked Questions
Why are EMA and AMA coordinating on Ebola now?
EMA says its Emergency Task Force is engaging AMA and African national regulators, with AVAREF expertise, to discuss clinical trial designs and medical countermeasures for the Bundibugyo virus outbreak in DRC and Uganda—the first such EMA–AMA emergency collaboration since AMA became operational.
Did WHO declare a PHEIC for Bundibugyo Ebola in 2026?
Yes. On 17 May 2026 the WHO Director-General determined that Ebola disease caused by Bundibugyo virus in DRC and Uganda constitutes a public health emergency of international concern under the IHR (2005), but not a pandemic emergency.
Are there licensed vaccines for Bundibugyo virus disease?
WHO states that unlike Zaire ebolavirus disease, there is no licensed vaccine or specific therapeutic against Bundibugyo virus, though early supportive care remains lifesaving.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
